 |
196 Products |  |
52 Diseases | | 196 Products |
|
3529 Trials |  |
15381 News |  |
| «12345678910111213...208209» |
- HR091506 / Jiangsu Hengrui Pharma
Efficacy and safety of HR091506 extended-release tablets in patients with gout, hyperuricemia, and recurrent flares, tophi, or chronic gouty arthropathy: a multicenter, randomized, double-blind phase 3 trial (N3) - May 5, 2026 - Abstract #EULAR2026EULAR_2934;
- |||| AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma, CS1002 (ipilimumab biosimilar) / CStone Pharma
Trial primary completion date: SHR-8068-301: A Clinical Study of SHR-8068 Combined With Adebrelimab and Bevacizumab Versus Sintilimab or Atezolizumab Combined With Bevacizumab for the Treatment of Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - May 4, 2026
P3, N=590, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Trial primary completion date: Mar 2026 --> Sep 2026
- | trastuzumab rezetecan (SHR-A1811) / Jiangsu Hengrui Pharma
New P2 trial: Exploratory Study of SHR-A1811 Via Different Administration Routes in Patients (clinicaltrials.gov) - May 2, 2026
P2, N=60, Not yet recruiting, Sponsor: Tianjin Medical University Cancer Institute and Hospital
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
Clinical, Retrospective data, Journal: Adjuvant camrelizumab for hepatocellular carcinoma patients with high risk of recurrence after curative hepatectomy: a retrospective multicenter study. (Pubmed Central) - May 1, 2026
Adjuvant camrelizumab may improve the prognosis of patients with HCC at high risk of recurrence after curative hepatectomy. Combination therapy with TKIs may be unnecessary.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab Plus S-1 for Resected Cholangiocarcinoma (clinicaltrials.gov) - May 1, 2026
P2, N=40, Not yet recruiting, Sponsor: Xingjun Guo
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
Journal, Mismatch repair: Case Report: A Case of Neuroendocrine Carcinoma of the Endometrium with Deficient DNA Mismatch Repair Had Achieved Clinical Complete Response after Combination Therapy. (Pubmed Central) - May 1, 2026
As a programmed death-1 (PD-1) inhibitor, camrelizumab has been proven to exhibit both efficacy and safety in the treatment of advanced dMMR solid tumors...Up to December 2024, the patient has survived 28 months since treatment, with 26 months free from disease progression, and the assessment indicated a status of clinical complete response (cCR). The combined regimen achieves notable efficacy and is free of unexpected adverse effects, with only a radiotherapy-related pelvic insufficiency fracture (PIF) report.
- ||| Clinical, P3 data, Retrospective data, Journal, Monotherapy: CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. (Pubmed Central) - May 1, 2026
Although all agents improved progression-free survival, only ribociclib and abemaciclib showed statistically significant overall survival benefits, whereas palbociclib did not, and data for dalpiciclib remain immature. Further head-to-head comparisons and assessments of toxicity profiles, as well as patient-reported outcomes, are needed.
- || ribupatide injection (HRS9531 injection) / Kailera Therapeutics
New P1 trial: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS9531 Injection in Adolescents With Obesity (clinicaltrials.gov) - Apr 30, 2026
P1, N=48, Not yet recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- ||| HRS-1780 / Jiangsu Hengrui Pharma
Enrollment open: A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism (clinicaltrials.gov) - Apr 30, 2026
P2, N=60, Recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
Further head-to-head comparisons and assessments of toxicity profiles, as well as patient-reported outcomes, are needed. Not yet recruiting --> Recruiting
- |||||| sonesitatug vedotin (AZD0901) / AstraZeneca
Enrollment open, Monotherapy: CLARITY-Gastric 01: AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (clinicaltrials.gov) - Apr 30, 2026
P3, N=572, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Active, not recruiting --> Recruiting
- | Meiyouheng (becotatug vedotin) / Lepu Med
New P2 trial: Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 30, 2026
P2, N=28, Not yet recruiting, Sponsor: Sun Yat-sen University
- |||||| Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
Enrollment open, Enrollment change, Trial initiation date: SHR8735-303: A Study to Evaluate the Efficacy and Safety of Hetrombopag Olamine Tablets Vs Placebo in Patients With Chemotherapy-Induced Thrombocytopenia (clinicaltrials.gov) - Apr 29, 2026
P3, N=58, Not yet recruiting, Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Active, not recruiting --> Recruiting N=34 --> 58 | Not yet recruiting --> Recruiting
- | zeprumetostat (SHR-2554) / Treeline Biosci, Lunsumio (mosunetuzumab-axgb) / Roche
New P2 trial: CUREFL03: Mosunetuzumab and Zeprumetostat in Treating Patients With Follicular Lymphoma (clinicaltrials.gov) - Apr 29, 2026
P2, N=80, Not yet recruiting, Sponsor: Institute of Hematology & Blood Diseases Hospital, China
- | Flarex (fluorometholone acetate ophthalmic suspension) / Harrow Health, Vevye (cyclosporine ophthalmic solution) / Novaliq, Harrow Health
New P4 trial: FLARE-VEV: Vevye + Flarex Combination Therapy for Dry Eye (clinicaltrials.gov) - Apr 28, 2026
P4, N=60, Enrolling by invitation, Sponsor: Canyon City Eyecare
- | HRS-7535 / Kailera Therapeutics
Enrollment open: Efficacy and Safety of Oral KAI-7535 in Adult Participants Living With Obesity or Overweight With at Least 1 Weight-Related Comorbidity (clinicaltrials.gov) - Apr 27, 2026
P2, N=320, Recruiting, Sponsor: Kailera
N=34 --> 58 | Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | AiTan (rivoceranib) / Elevar Therapeutics
Journal: Characterization of forced degradation products of tyrosine kinase inhibitor apatinib mesylate by LC-MS/MS and NMR with in silico toxicity assessment. (Pubmed Central) - Apr 27, 2026
Not yet recruiting --> Recruiting In silico toxicity profile for APA and its DPs was evaluated by ADMET Predictor
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., AiRuiKa (camrelizumab) / Elevar Therapeutics
Biomarker, Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker: Intratumoral Proton Density Fat Fraction Predicts the Outcome of HAIC Combined With PD-1 Inhibitors in Advanced Hepatocellular Carcinoma. (Pubmed Central) - Apr 27, 2026
Baseline intratumoral PDFF may serve as a promising imaging biomarker associated with treatment response in patients receiving HAIC-PD1 therapy. Its potential prognostic relevance for time-to-event outcomes requires further validation in prospective cohorts.
- AiTan (rivoceranib) / Elevar Therapeutics, AiRuiKa (camrelizumab) / Elevar Therapeutics
Efficacy and Safety of Camrelizumab Plus Apatinib Combined with Brachytherapy in Previously Treated Recurrent or Metastatic Cervical Cancer: A Prospective Single-Center Study (Exhibition) - Apr 24, 2026 - Abstract #ESMOGynae2026ESMO_Gynae_174;
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
Adebrelimab in the Adjuvant Treatment of Esophageal Squamous Cell Carcinoma: A Randomized Controlled Clinical Trial?PAIT-ESCC-0825? (Foyer) - Apr 24, 2026 - Abstract #ESMOGI2026ESMO_GI_886;
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Camrelizumab combined with chemotherapy as neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma: A long-term retrospective study (Foyer) - Apr 24, 2026 - Abstract #ESMOGI2026ESMO_GI_864;
Its potential prognostic relevance for time-to-event outcomes requires further validation in prospective cohorts. lesion length (<7cm vs. ?7cm) as an independent prognostic factor for OS (HR, 1.96; 95% CI, 1.11
- AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
A Clinical Study of Adebrelimab Combined with CyberKnife in Advanced Pancreatic Cancer and Intra- and Extrahepatic Cholangiocarcinoma (Foyer) - Apr 24, 2026 - Abstract #ESMOGI2026ESMO_GI_851;
- AiTan (rivoceranib) / Elevar Therapeutics
Surgical safety and efficacy of neoadjuvant PD-1 inhibitors plus apatinib and chemotherapy in locally advanced gastric cancer (Foyer) - Apr 24, 2026 - Abstract #ESMOGI2026ESMO_GI_713;
Conclusions The PAC regimen significantly improves pathological response and survival in LAGC without compromising surgical safety. Combining effective systemic therapy with precision surgical techniques optimizes perioperative outcomes.
- AiRuiKa (camrelizumab) / Elevar Therapeutics
Phase II exploratory study on neoadjuvant short-course radiotherapy with target volume optimization, chemotherapy, and camrelizumab for esophageal squamous cell carcinoma (Foyer) - Apr 24, 2026 - Abstract #ESMOGI2026ESMO_GI_711;
P2
Conclusions Neoadjuvant short-course radiotherapy plus concurrent chemotherapy and camrelizumab is safe in patients with ESCC, with no delays in surgery, and induces pCR in 53.33% of resected tumors. Our findings support this regimen is a promising neoadjuvant therapy for locally advanced ESCC.
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New trial, Real-world evidence: Efficacy and Safety of Switching to Ivarmacitinib in Patients With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to Interleukin-4 Receptor Alpha(IL-4R?) Inhibitors: A Prospective, Multicenter, Real-World Study (clinicaltrials.gov) - Apr 24, 2026
P=N/A, N=300, Not yet recruiting, Sponsor: Peking University People's Hospital
- |||||||||| ribupatide injection (HRS9531 injection) / Kailera Therapeutics
New P3 trial: A Phase III Study To Evaluate the Efficacy And Safety Of HRS9531 In Participants With Atherosclerotic Cardiovascular Disease (clinicaltrials.gov) - Apr 24, 2026
P3, N=9262, Not yet recruiting, Sponsor: Fujian Shengdi Pharmaceutical Co., Ltd.
- | Journal: GAP mimetic activity of pan-Ras TCI daraxonrasib synergizes with K-Ras Switch-II pocket inhibition. (Pubmed Central) - Apr 24, 2026
These findings establish GAP mimetics as rational and potent combination partners for Switch-II pocket inhibitors. The synergistic combination has potential to deepen and prolong pathway suppression while enabling dose reductions that may mitigate on-target toxicity and resistance.
- | Itari (linperlisib) / Shanghai YingLi Pharma, Copiktra (duvelisib) / Secura Bio, Yakult Honsha
Journal, HEOR, Cost-effectiveness: Cost-Effectiveness Analysis of PI3K Inhibitors for Relapsed or Refractory Follicular Lymphoma in China: A Comparison Between Linperlisib and Duvelisib. (Pubmed Central) - Apr 23, 2026
P2
Linperlisib is cost effective compared to duvelisib for 3L+ FL patients in China, as verified in sensitivity analyses. Further study is warranted to confirm that it meets an unmet need in China.
- | AiTan (rivoceranib) / Elevar Therapeutics, eribulin mesylate / Generic mfg., AiRuiKa (camrelizumab) / Elevar Therapeutics
Enrollment open, Trial completion date, Trial primary completion date: Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer (clinicaltrials.gov) - Apr 23, 2026
P3, N=246, Recruiting, Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Further study is warranted to confirm that it meets an unmet need in China. Active, not recruiting --> Recruiting | Trial completion date: Mar 2031 --> Jun 2029 | Trial primary completion date: Sep 2030 --> Dec 2028
- | Irene (pyrotinib) / Jiangsu Hengrui Pharma, TheraCIM (nimotuzumab) / Daiichi Sankyo, Biocon, Biotech Pharma, Halaven (eribulin mesylate) / Eisai
New P2 trial: A multicenter, single-arm phase II clinical study of eribulin combined with inituzumab and pyrotinib in the treatment of HER2-positive advanced breast cancer (EUDRACT) - Apr 23, 2026
P2, N=76, Recruiting, Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University; Fifth Affiliated Hospital, Sun Yat-Sen University
- | AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New trial: A Phase II Prospective Clinical Study of Adebrelimab combined with Chemotherapy as First-Line Treatment for Advanced Non-Small Cell Lung Cancer Complicated with Chronic Obstructive Pulmonary Disease (EUDRACT) - Apr 23, 2026
P=N/A, N=60, , Sponsor: inling Hospital, Affiliated Hospital of Medical School, Nanjing University; Jinling Hospital, Affiliated Hospital of Medical School, Nanjing Universit
- | AiTan (rivoceranib) / Elevar Therapeutics, retlirafusp alfa (SHR-1701) / Jiangsu Hengrui Pharma
New P4 trial: A clinical study of retlirafusp alfa combined with platinum-based chemotherapy and apatinib as first-line treatment for advanced NSCLC (EUDRACT) - Apr 23, 2026
P4, N=35, , Sponsor: The first affiliated hospital of anhui medical university; The first affiliated hospital of anhui medical university
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis, AnDaJing (vunakizumab) / Jiangsu Hengrui Pharma
New P4 trial: VIVA-TAK: Comparing the efficacy and safety of Funachizumab and Amgxitinib in the treatment of large artery vasculitis (EUDRACT) - Apr 23, 2026
P4, N=180, , Sponsor: Peking Union Medical College Hospital; Peking Union Medical College Hospital
- | AiTan (rivoceranib) / Elevar Therapeutics, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P2 trial: Adebrelimab combined with apatinib and platinum-based chemotherapy for neoadjuvant treatment of potentially resectable thymic carcinoma: A single-center, single-arm, phase II clinical study (EUDRACT) - Apr 23, 2026
P2, N=20, , Sponsor: Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University); Jiangsu Province Hospital (The First Affiliated Hospital wi
- | AiTan (rivoceranib) / Elevar Therapeutics, Lynparza (olaparib) / Merck (MSD), AstraZeneca
New P2 trial, Platinum sensitive: Clinical study on maintenance therapy of olaparib combined with apatinib in patients with platinum-sensitive recurrent ovarian cancer (EUDRACT) - Apr 23, 2026
P2, N=34, , Sponsor: Anqing Municipal Hospital; Anqing Municipal Hospital
- | Sufenta (sufentanil) / Akorn, AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial, Adverse events: Comparison of Tegileridine fumarate and Sufentanil citrate for postoperative analgesia and adverse events after transsphenoidal surgery for pituitary adenoma (EUDRACT) - Apr 23, 2026
P=N/A, N=150, , Sponsor: The First Affiliated Hospital of University of Science and Technology of China; The First Affiliated Hospital of University of Science and Technology
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
New trial: Efficacy and Safety of Interferon-Gamma Combined with Camrelizumab in Neoadjuvant Therapy for Locally Advanced Esophageal Squamous Cell Carcinoma (EUDRACT) - Apr 23, 2026
P=N/A, N=84, , Sponsor: Hefei Cancer Hospital, Chinese Academy of Sciences; Hefei Cancer Hospital, Chinese Academy of Sciences
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: The effect of tegileridine on remifentanil-induced hyperalgesia after laparoscopic surgery: A clinical randomized controlled trial (EUDRACT) - Apr 23, 2026
P4, N=68, Recruiting, Sponsor: chongqing university cancer hospital; chongqing university cancer hospital
- | Sufenta (sufentanil) / Akorn, remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: The effect of remimazolam mesylate versus propofol on postoperative fatigue syndrome in patients with laparoscopic colorectal cancer: A randomized controlled trial (EUDRACT) - Apr 23, 2026
P=N/A, N=92, , Sponsor: The Affiliated Hospital of Xuzhou Medical University; The Affiliated Hospital of Xuzhou Medical University
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New P4 trial: Efficacy and safety of Tegileridine Fumarate Injection for postoperative analgesia in video-assisted thoracoscopic surgery (VATS),a multicenter prospective randomized controlled clinical study (EUDRACT) - Apr 23, 2026
P4, N=426, , Sponsor: Renmin Hospital of Wuhan University; Renmin Hospital of Wuhan University
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New trial: Exploratory Clinical Study on the Efficacy and Safety of Herombopag Olamine Tablets in Combination with Immunosuppressive Therapy for Children with Primary Aplastic Anemia (EUDRACT) - Apr 23, 2026
P=N/A, N=60, , Sponsor: The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Cancer Hospital); The First Affiliated Hospital of Un
- | AiSuTe (tegileridine) / Jiangsu Hengrui Pharma
New trial: Dose-response relationship of tegileridine in inhibiting the response to laryngeal mask airway insertion during etomidate induction in elderly patients: A sequential trial. (EUDRACT) - Apr 23, 2026
P=N/A, N=40, Recruiting, Sponsor: The second hospital & clinical medical school.lanzhou university; The second hospital & clinical medical school.lanzhou university
- | AiSuDa (ivarmacitinib) / Jiangsu Hengrui Pharma, Arcutis
New P4 trial: Evaluation of Efficacy and Safety of Ivarmacitinib Tablets in Adults with Moderate to Severe Hidradenitis Suppurativa: A Prospective, Single-Arm, Multicenter Study (EUDRACT) - Apr 23, 2026
P4, N=20, , Sponsor: West China Hospital, Sichuan University; West China Hospital, Sichuan University
- | risvutatug rezetecan (GSK5764227) / GSK, AiRuiLi (adebrelimab) / Jiangsu Hengrui Pharma
New P3 trial: HS-20093-309: A Multicenter, Randomized, Open-Label, Controlled Phase III Clinical Study Evaluating the Efficacy and Safety of HS-20093 Injection Combined with Adebrelimab versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer without Actionable Genomic Alterations (EUDRACT) - Apr 23, 2026
P3, N=450, , Sponsor: Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital
- | sevoflurane / Generic mfg.
New trial: A Randomized Controlled Trial: Effects of Remimazolam, Propofol, and Sevoflurane on Postoperative Fatigue after Laparoscopic Gynecological Surgery (EUDRACT) - Apr 23, 2026
P=N/A, N=120, Completed, Sponsor: Baotou Central Hospital; Baotou Central Hospital
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
New P4 trial: Camrelizumab combined with thalidomide sequential treatment for unresectable locally advanced esophageal squamous cell carcinoma after concurrent chemoradiotherapy: A prospective, multicenter, single-arm, exploratory study (EUDRACT) - Apr 23, 2026
P4, N=50, Completed, Sponsor: Suzhou Municipal Hospital; Suzhou Municipal Hospital
- | Hengqu (hetrombopag) / Jiangsu Hengrui Pharma
New trial: A Single-Center, Exploratory Clinical Study on the Efficacy and Safety of Hetrombopag in the Treatment of Chemotherapy-Induced Thrombocytopenia in Nasopharyngeal Carcinoma (EUDRACT) - Apr 23, 2026
P=N/A, N=68, , Sponsor: Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center
- | remimazolam tosylate (HR-7056) / Jiangsu Hengrui Pharma
New trial: Comparison of the Safety of Remimazolam Tosilate and Propofol in Non-intubated General Anesthesia for Gastrointestinal Endoscopy Based on Dynamic Trajectories of Vital Signs Monitored by Wearable Devices: A Prospective Randomized Controlled Study (EUDRACT) - Apr 23, 2026
P=N/A, N=260, , Sponsor: The Second People's Hospital of Chengdu, Sichuan University; The Second People's Hospital of Chengdu, Sichuan University,
- | recaticimab (SHR-1209) / Jiangsu Hengrui Pharma
New P4 trial: REcaticimab for Vascular Efficacy in ReverSing coronary athErosclerotic Plaques: A Multicenter, Prospective, Open-Label, Pragmatic Randomized Controlled Trial (EUDRACT) - Apr 23, 2026
P4, N=1482, , Sponsor: The second affiliated hospital of Zhejiang University school of medicine; The second affiliated hospital of Zhejiang University school of medicine
- | AiRuiEn (rezvilutamide) / Jiangsu Hengrui Pharma
New trial: Open-label, single-arm, prospective clinical study of rezvilutamide combined with docetaxel and androgen deprivation therapy for high-volume metastatic hormone-sensitive prostate cancer (EUDRACT) - Apr 23, 2026
P=N/A, N=43, , Sponsor: The First Bethune Hospital of Jilin University; The First Bethune Hospital of Jilin University
- | AiRuiKa (camrelizumab) / Elevar Therapeutics
New trial: Efficacy and Mechanism of Camrelizumab in Combination with Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study (EUDRACT) - Apr 23, 2026
P=N/A, N=30, , Sponsor: Harbin Medical University Cancer Hospital; Harbin Medical University Cancer Hospital